ArticleScientific reports2024

ER+/PR- phenotype exhibits more aggressive biological features and worse outcome compared with ER+/PR+ phenotype in HER2-negative inflammatory breast cancer.

Yunbo Luo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.